Type I interferon pushes lung immune cells toward injury after radiation
Radiation-induced lung injury remains one of the most consequential toxicities in thoracic radiotherapy, especially when dose escalation is needed to control lung cancer. In a preclinical mouse model, a high-dose, restricted-field regimen aimed at the left lung triggered a measurable immune shift: resident ILC2 populations moved toward a more inflammatory ILC1 phenotype. The work places type I interferon signaling at the center of that transition and links the pathway to tissue damage after irradiation.
The biology fits the clinical problem. Radiation damages epithelial and endothelial cells, then drives a cascade of inflammatory mediators that can evolve into pneumonitis and, later, fibrosis. Innate lymphoid cells sit close to the airway mucosa and respond quickly to tissue stress, so a shift from type 2 to type 1 programming can amplify local inflammation rather than restrain it. In this model, that immune reprogramming appears to be part of the mechanism by which radiation converts a targeted treatment into collateral lung injury.
Single-cell profiling connected type I interferon to ILC2-to-ILC1 plasticity
Flow cytometry and cytokine profiling showed a radiation-induced change in the balance of lung ILC populations. Instead of preserving a type 2-skewed mucosal profile, the irradiated lungs showed movement toward pro-inflammatory type 1 cells. Single-cell RNA sequencing deepened the signal by suggesting that type I interferon promotes this plasticity, providing a plausible molecular bridge between DNA damage sensing and the immune phenotype that followed.
A one-sentence takeaway stands out: radiation did not simply injure lung tissue; it altered the identity of the innate lymphoid compartment.
That cellular reprogramming matters because ILC2s and ILC1s do not perform interchangeable roles. ILC2s are generally associated with tissue repair and type 2 immunity, while ILC1s support interferon-linked inflammatory responses. A shift toward ILC1-like behavior after radiation therefore offers a direct route to sustained inflammatory signaling, more immune-mediated injury, and a setting more favorable to pneumonitis progression.
IFN-β reproduced the inflammatory switch in mouse and human cells
The in vitro experiments gave the mechanism practical shape. When mouse ILC2s were exposed to IFN-β, they increased expression of the ILC1-associated markers T-bet and IFN-γ. In parallel, IFN-β stimulation of human peripheral blood mononuclear cells increased the ILC1-to-ILC2 ratio. Even though one experiment used mouse cells and the other used human peripheral blood cells, both systems pointed in the same direction: type I interferon favors an inflammatory ILC profile.
That consistency strengthens the translational appeal of the pathway. The human PBMC finding does not prove that the same shift occurs in irradiated patients, but it does show that human immune cells can respond to IFN-β with the same directional bias seen in the mouse lung model. In a clinical setting, that kind of immune skew could help explain why some patients develop outsized pulmonary inflammation after radiotherapy even when the tumor target is well defined.
Blocking type I interferon signaling reduced lung damage in vivo
The most clinically relevant finding came from the in vivo inhibition experiments. Suppressing type I IFN signaling attenuated lung damage after irradiation in the mouse RILI model. That result does not erase the benefit of radiation against cancer, but it does suggest that part of the normal tissue response is biologically modifiable. If the interferon-driven shift can be interrupted, the lung may be less likely to move from acute inflammatory injury into the longer injury trajectory that leads to symptomatic pneumonitis and fibrosis.
The practical implication is straightforward: a pathway generated by radiation itself may be a therapeutic vulnerability. Radiation creates nucleic-acid stress, activates innate immune sensing, and then appears to feed a type I IFN signal that pushes ILCs toward a more inflammatory state. Interfering at that node could, in principle, preserve antitumor benefit while reducing normal lung toxicity. Any such strategy would still need careful testing, because dampening interferon signaling could also alter anti-tumor immunity or host defense.
Why this mechanism matters for thoracic radiotherapy
RILI is not just a radiographic change. It can progress to clinically meaningful respiratory compromise, including pneumonitis and fibrosis, and it remains a dose-limiting toxicity in lung cancer radiotherapy. The current study adds immune-cell plasticity to the list of contributors already known to shape risk, including dose per fraction, irradiated lung volume, and tumor location. By focusing on innate lymphoid cells, the work moves beyond broad inflammation and identifies a specific cellular switch that may sit between radiation exposure and tissue injury.
A brief note on the pathophysiology is warranted. Type I interferons are often viewed through the lens of antiviral defense, but in sterile tissue injury they can also amplify inflammatory circuits. Here, that same signaling axis appears to reassign ILC2s away from their usual tissue-supportive program and toward an IFN-γ-producing phenotype. In the context of irradiated lung, such a shift can intensify macrophage recruitment, cytokine release, and epithelial stress, all of which can feed the damage response.
The translational gap remains the next hurdle
This is preclinical work, and the step from mouse lung injury to bedside prevention is still substantial. The model used high-dose restricted-field irradiation to the left lung, which is useful for mechanism but cannot capture the full heterogeneity of human thoracic radiotherapy, underlying lung disease, concurrent systemic therapy, or individual radiosensitivity. The human data also came from peripheral blood mononuclear cells rather than irradiated lung tissue, so the study supports biological plausibility more strongly than direct clinical prediction.
Even with those limits, the direction of travel is clear. Type I interferon signaling emerges as a candidate driver of radiation-induced lung injury, and ILC2-to-ILC1 plasticity gives the finding a cellular mechanism that can be tested further. The next questions are concrete: whether the same immune shift occurs in patients receiving lung radiotherapy, whether it predicts symptomatic injury, and whether pathway inhibition can protect normal lung without compromising tumor control.